On July 25 2016, Protelica announced an equity investment and strategic partnership with Beijing Sinobioway Group Company, Limited (Sinobioway), a China-based investors group affiliated to the largest biotech organization in China. The proceeds will be used to accelerate the development of Protelica’s Pronectin™ therapeutic platform. This strategic investment will also advance Protelica’s plans to collaboratively develop biotherapeutics with biopharmaceutical companies in China to address the growing demand for innovative therapeutic products in the Chinese pharmaceutical market. As part of the deal, Protelica and Sinobioway will also establish joint operation with facilities in Hefei, China which will have preclinical and clinical development capabilities in order to develop, manufacture and commercialize Pronectin™ therapeutics.
Sinobioway is the largest biotech organization in China that includes more than 100 affiliates. Sinobioway Group Co., Ltd. (Sinobioway), founded in 1992, is one of the three main industrial groups affiliated with Peking University. Sinobioway is mainly engaged in bioeconomy system establishment and bio-industry development. It primarily invests in biomedicine, bioagriculture, bioenergy, bioenvironment, bioservices, biomanufacturing and biointelligence.
Sinobioway Bantang Bioeconomy Icubator in Hefei, Anhui
Protelica is focused initially on developing oncology products where there is a significant benefit for patients, including targeted therapies for cancer types that are deemed intractable by currently available small molecule and monoclonal antibody therapies. Protelica is interested in establishing a portfolio of strategic collaborations with key partners and is open to discuss areas of potential common interest in the oncology space from which to build value for both parties. To discuss partnering opportunities in oncology, please contact us at email@example.com